Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a potential first-in-class mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis and Phase 2 development for systematic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T. For more information, please visit www.cartesiantherapeutics.com
Company Details
- Employees
- 85
- Founded
- -
- Address
- 7495 New Horizon Way, Frederick,maryland 21703,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- cartesiantherapeutics.com
- Keywords
- Immunotherapy, Oncology, Molecular Biology, Immunology, Myasthenia Gravis, ARDS, Cell Therapy, NETs, Gene Therapy, Cancer Research, multiple myeloma, SLE, mRNA, CAR-T, Systemic lupus erythematosus, Autoimmunity, Autoimmune Disease, Lupus.
- HQ
- Frederick, Maryland
Cartesian Therapeutics Questions
Cartesian Therapeutics's website is cartesiantherapeutics.com
Cartesian Therapeutics's LinkedIn profile is https://www.linkedin.com/company/cartesian-therapeutics
Cartesian Therapeutics has
85 employees.
View email and phone details for 85
employees at Cartesian Therapeutics.
Cartesian Therapeutics's industry is
Biotechnology Research
Cartesian Therapeutics's top competitors are
Kyverna Therapeutics,
Theradaptive,
Novavax,
Selecta Biosciences,
Integerbio,
Kite Pharma,
Precigen,
Beacon Therapeutics,
Arcellx,
Valogic Bio.
Cartesian Therapeutics's categories are Biotechnology Research
Cartesian Therapeutics's founding year is 2016
